

Edgar Filing: Recro Pharma, Inc. - Form SC 13G/A

Recro Pharma, Inc.  
Form SC 13G/A  
February 14, 2018

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

SCHEDULE 13G  
(Amendment 1)  
Under the Securities Exchange Act of 1934

(Name of Issuer) Recro Pharma, Inc.  
(Title of Class of Securities) Common Stock  
(CUSIP Number) 75629F109  
(Date of Event Which Requires Filing of this Statement) December 31, 2017

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

- Rule 13d-1(b)
- Rule 13d-1(c)
- Rule 13d-1(d)

CUSIP No. 75629F109

1. Names of Reporting Persons.

Laurence W. Lytton

2. Check the Appropriate Box if a Member of a Group (See Instructions)

- a) .....
- (b) .....

3. SEC Use Only

4. Citizenship or Place of Organization

USA

5. Sole Voting Power 859,281

6. Shared Voting Power 18,700

7. Sole Dispositive Power 859,281

8. Shared Dispositive Power 18,700

9. Aggregate Amount Beneficially Owned by Each Reporting Person

877,981

10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) .....

## Edgar Filing: Recro Pharma, Inc. - Form SC 13G/A

11. Percent of Class Represented by Amount in Row (9)

4.6% (1)

(1) Based on 19,123,935 shares outstanding As of November 7, 2017 as reported in the Sept 30, 2017 10-Q.

12. Type of Reporting Person (See Instructions)

IN

Item 1.

(a) Name of Issuer Recro Pharma, Inc.

(b) Address of Issuer's Principal Executive Offices

490 Lapp Road, Malvern,  
Pennsylvania 19355

Item 2.

(a) Name of Person Filing Laurence W. Lytton

(b) Address of Principal Business Office or, if none, Residence

467 CPW  
N.Y., NY 10025

(c) Citizenship USA

(d) Title of Class of Securities Common

(e) CUSIP Number 75629F109

Item 3. not applicable

Item 4. Ownership.

(a) Amount beneficially owned: 877,981 consisting of 636,106 shares held by the reporting person, 65,763 held in the AWL Family LLC, 66,759 held in the IKL Trust, 53,162 held in the KLL Family Trust, 32,391 held in the L-K Foundation, and 23,800 shares held in other related accounts.

(b) Percent of class: 4.6%

(c) Number of shares as to which the person has:

(i) Sole power to vote or to direct the vote 859,281

(ii) Shared power to vote or to direct the vote 18,700

(iii) Sole power to dispose or to direct the disposition of 859,281

(iv) Shared power to dispose or to direct the disposition of 18,700

Edgar Filing: Recro Pharma, Inc. - Form SC 13G/A

Item 5. Ownership of Five Percent or Less of a Class:

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following (X).

Item 6. Ownership of More than Five Percent on Behalf of Another Person.

Not applicable

Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company

Not applicable

Item 8. Identification and Classification of Members of the Group

Not applicable

Item 9. Notice of Dissolution of Group

Not applicable

Item 10. Certification

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

2/14/18\_\_\_\_\_

Date

\_\_\_\_s/ Laurence W. Lytton\_\_\_\_\_

Signature

\_\_\_\_Laurence W. Lytton\_\_\_\_\_

Name/Title